M344: Potent HDAC Inhibitor (IC50 100 nM) for Cancer and HIV-1 Research

Executive Summary: M344 is a histone deacetylase (HDAC) inhibitor with nanomolar potency (IC50 = 100 nM) and high cell permeability, enabling robust modulation of gene expression and apoptosis induction in diverse cancer lines (APExBIO). It demonstrates GI50 values of 0.63–0.65 μM in MCF-7 (breast), D341 MED (medulloblastoma), and CH-LA 90 (neuroblastoma) cells, supporting its broad applicability. M344 enhances the efficacy of radiation therapy in squamous carcinoma models, regulates factors such as NF-κB, and induces pro-apoptotic proteins like Puma via p53-independent pathways. Its solubility profile (ethanol ≥12.88 mg/mL, DMSO ≥14.75 mg/mL) and recommended storage conditions (-20°C, avoid long-term solutions) make it suitable for reproducible research workflows. M344 is for research use only and is supplied as a solid for precise experimental control (APExBIO).

Biological Rationale

Histone deacetylases (HDACs) play a central role in epigenetic regulation by removing acetyl groups from lysine residues on histone tails, resulting in chromatin condensation and transcriptional repression. In many malignancies, aberrant HDAC activity is associated with oncogenic gene silencing and impaired cellular differentiation (M344: Unraveling Epigenetic Mechanisms). HDAC inhibition reverses these effects, leading to increased histone acetylation, chromatin relaxation, and activation of tumor suppressor genes. Compounds like M344 are instrumental for dissecting HDAC-dependent signaling and its impact on tumorigenesis, cell cycle regulation, and viral latency, including in HIV-1 reservoirs (M344: Potent HDAC Inhibitor).

Mechanism of Action of M344

M344 acts as a reversible, cell-permeable inhibitor of class I and II HDACs. By inhibiting HDAC activity, M344 increases global and locus-specific histone acetylation. This modification enhances access for transcription factors and the basal transcriptional machinery, reactivating silenced genes (M344: Mechanistic Insights). M344 has been shown to induce pro-apoptotic proteins such as Puma via pathways independent of p53, and to modulate key transcription factors including NF-κB. In HIV-1 research, M344 can stimulate the HIV-1 long terminal repeat (LTR), reversing viral latency and highlighting its potential in 'shock and kill' therapeutic strategies.

Evidence & Benchmarks

• M344 inhibits HDAC with an IC50 of 100 nM in enzymatic assays at 25°C, pH 7.5, using a fluorometric substrate (APExBIO).
• Demonstrates GI50 values of 0.63 μM (MCF-7 breast cancer), 0.65 μM (D341 MED medulloblastoma), and 0.65 μM (CH-LA 90 neuroblastoma) after 72-hour incubation in RPMI-1640 medium (APExBIO).
• Enhances radiosensitivity in human squamous carcinoma cell lines SCC-35 and SQ-20B when co-administered at 1–10 μM for 24–48 hours before irradiation (APExBIO).
• Induces Puma expression and apoptosis in neuroblastoma cells via p53-independent mechanisms, as measured by caspase-3 activation assays (M344: Mechanistic Insights).
• Activates HIV-1 LTR-driven gene expression in latency models at concentrations of 1–10 μM, with peak response at 24–48 hours post-treatment (M344: Potent HDAC Inhibitor).
• Soluble in DMSO at ≥14.75 mg/mL (room temperature, ultrasonic treatment), insoluble in water (APExBIO).
• Recommended storage: -20°C, protected from light, avoid repeated freeze-thaw cycles (APExBIO).

Applications, Limits & Misconceptions

M344 is primarily used in basic and translational research for:

• Apoptosis assays in oncology, leveraging its ability to induce cell death in cancer lines.
• Studies of cell differentiation and proliferation, especially in epigenetic reprogramming contexts.
• HIV-1 latency reversal, as a tool for activating latent proviruses in ex vivo and in vitro systems.
• Radiation sensitization in preclinical cancer models.

For a practical, scenario-driven guide on integrating M344 into diverse biomedical workflows, see M344 (SKU A4105): Scenario-Driven Solutions; this article extends those recommendations by providing updated quantitative benchmarks and evidence from recent cancer and HIV-1 studies.

Common Pitfalls or Misconceptions

• M344 is not water-soluble and should not be prepared in aqueous buffers; use DMSO or ethanol with ultrasonic treatment for dissolution (APExBIO).
• Not suitable for in vivo or clinical use; intended for laboratory research only.
• Long-term storage in solution form leads to degradation; only keep stock solutions at -20°C for short periods.
• Effective concentrations and durations may vary by cell type; excessive dosing can cause off-target cytotoxicity.
• M344 is not a substitute for selective HDAC isoform inhibitors; it affects multiple HDAC classes.

Workflow Integration & Parameters

For optimal results, dissolve M344 in DMSO (≥14.75 mg/mL) or ethanol (≥12.88 mg/mL) using ultrasonic treatment. Prepare fresh working solutions prior to use, and avoid repeated freeze–thaw cycles. Recommended experimental concentrations range from 1 μM to 100 μM, with treatment durations from 1 to 7 days depending on the model. For apoptosis and cell cycle assays, 24–72 hours of exposure is typical. M344 is supplied as a solid, shipped on blue ice, and should be handled with standard laboratory safety protocols (APExBIO). For advanced workflow examples or troubleshooting, Rewriting the Epigenetic Script offers strategic guidance not covered in this dossier.

Conclusion & Outlook

M344, distributed by APExBIO, is a validated, potent, and cell-permeable HDAC inhibitor with broad utility in cancer and HIV-1 research. Its quantitative benchmarks and mechanistic specificity support robust experimental outcomes, provided solubility and storage parameters are observed. Ongoing research may further elucidate its selectivity profile and expand its applications in combinatorial epigenetic therapies. For the most up-to-date protocols and validated use-cases, refer to the M344 product page and recent peer-reviewed studies.